Johnson & Johnson Sees Path to Double-Digit Growth Despite Patent Expirations in 2026
Johnson & Johnson (JNJ) is confident it can achieve double-digit growth over the next several years, surpassing its current long-term target of 5%–7%. This optimism stems from a robust pharmaceutical pipeline and MedTech portfolio. The company anticipates facing $4 billion to $4.5 billion in revenue loss due to patent expirations for key products like XARELTO, SIMPONI, STELARA, and pulmonary hypertension drugs by 2026 but believes its marketed products and late-stage pipeline will offset these losses. J&J expects around $21 billion in free cash flow this year, which supports its dividend policy and provides flexibility for strategic acquisitions. The company is also positioning itself with the newly approved OTTAVA surgical robotics platform as a long-term growth driver. CFO Joe Wolk emphasized that J&J does not rely on pricing gains or acquisitions to meet its growth targets but rather focuses on market leadership in key therapeutic areas like oncology, immunology, and neuroscience.
Tickers: $JNJ
Topics: growth strategy medtech patent cliff pharmaceuticals